Impact of ABO incompatibility on engraftment and transfusion requirement after unrelated cord blood transplantation: A single institute experience in Japan

Bone Marrow Transplantation

Volumn 40, Issue 6, 2007, Pages 523-528

  Tomonari, A ^a   Takahashi, S ^a   Ooi, J ^a   Tsukada, N ^a   Konuma, T ^a   Kobayashi, T ^a   Sato, A ^a   Iseki, T ^a   Yamaguchi, T ^a   Tojo, A ^a   Asano, S ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b WASEDA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; METHOTREXATE;

ADULT; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CORD BLOOD STEM CELL TRANSPLANTATION; DONOR; ENGRAFTMENT; ERYTHROCYTE TRANSFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HAZARD RATIO; HUMAN; HUMAN TISSUE; INCIDENCE; JAPAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RECIPIENT; THROMBOCYTE TRANSFUSION;

ABO BLOOD-GROUP SYSTEM; ADOLESCENT; ADULT; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; HEMOLYSIS; HISTOCOMPATIBILITY; HUMANS; JAPAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPHILS; PLATELET TRANSFUSION; RED-CELL APLASIA, PURE; RISK FACTORS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 34548524030     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705765     Document Type: Article

References (20)

1. O'Donnell MR. Blood group incompatibilities and hemolytic complications of hematopoietic cell transplantation. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation. Blackwell Scientific Publications: Oxford, 2004, pp 824-432.
2. Rozman P, Kosir A, Bohinjec M. Is the ABO incompatibility a risk factor in bone marrow transplantation? Transplant Immunol 2005; 14: 159-169.
3. Lee JH, Lee KH, Kim S, Lee JS, Kim SH, Kwon SW et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25: 179-184.
4. Bolan CD, Leitman SF, Griffith LM, Wesley RA, Procter JL, Stroncek DF et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyelo-ablative hematopoietic stem cell transplantation. Blood 2001; 98: 1687-1694.
5. Seebach JD, Stussi G, Passweg JR, Loberiza Jr FR, Gajewski JL, Keating A et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant 2005; 11: 1006-1013.
6. Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004; 104: 3813-3820.
7. Lasky LC, Warkentin PI, Kersey JH, Ramsay NK, McGlave PB, McCullough J. Hemotherapy in patients undergoing blood group incompatible bone marrow transplantation. Transfusion 1983; 23: 277-285.
8. Friedberg RC. Transfusion therapy in hematopoietic stem cell transplantation. In: Mintz PD (ed). Transfusion Therapy: Clinical Principles and Practice. AABB Press: Bethesda, MD, 1999, pp 233-249.
9. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706.
10. Mielcarek M, Leisenring W, Torok-Storb B, Storb R. Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: Evidence for a graft-versus-plasma cell effect. Blood 2000; 96: 1150-1156.
11. Peggs KS, Morris EC, Kottaridis PD, Geary J, Goldstone AH, Linch DC et al. Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen. Blood 2002; 99: 4642-4643.
12. Santamaria A, Sureda A, Martino R, Domingo-Albos A, Muniz-Diaz E, Brunet S. Successful treatment of pure red cell aplasia after major ABO-incompatible T cell depleted bone marrow transplantation with erythropoietin. Bone Marrow Transplant 1997; 20: 1105-1107.
13. Roychowdhury DF, Linker CA. Pure red cell aplasia complicating an ABO compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin. Bone Marrow Transplant 1995; 16 471-472.
14. Bavaro P, Di Girolamo G, Olioso P, Papalinetti G, Iacone A, Accorsi P et al. Donor lymphocyte infusion as therapy for pure red cell aplasia following bone marrow transplantation. Br J Haematol 1999; 104 930-931.
15. Maschan AA, Skorobogatova EV, Balashov DN, Pashanov ED, Trakhtman PE, Schipitzina IP et al. Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia. Bone Marrow Transplant 2002; 30: 405-407.
16. Badros A, Tricot G, Toor A, Morris C, Guo C, Munshi N et al. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion 2002; 42: 205-209.
17. Dunstan RA, Simpson MB, Knowles RW, Rosse WF. The origin of ABH antigens on human platelets. Blood 1985; 65: 615-619.
18. Cooling LL, Zhang D, Koerner TA. Human platelets express gangliosides with LKE activity and ABH blood group activity. Transfusion 2001; 41: 504-516.
19. Stussi G, Muntwyler J, Passweg JR, Seebach L, Schanz U, Gmur J et al. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30: 87-93.
20. Erker CG, Steins MB, Fischer RJ, Kienast J, Berdel WE, Sibrowski W et al. The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation. Transfusion 2005; 45: 1382-1390.